Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice

Expert Opinion on Drug Safety

Volumn 18, Issue 5, 2019, Pages 415-425

  Cantini, Fabrizio ^a   Niccoli, Laura ^a   Capone, Alessandro ^b   Petrone, Linda ^b   Goletti, Delia ^b  

^a Hospital of Prato   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

csDMARDs; LTBI; non anti TNF biologics; tuberculosis

Indexed keywords

ABATACEPT; AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOSPORINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; SARILUMAB; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; ANTIRHEUMATIC AGENT;

CORTICOSTEROID THERAPY; HUMAN; INFECTION RISK; LATENT TUBERCULOSIS; REVIEW; RHEUMATIC DISEASE; MASS SCREENING; PRACTICE GUIDELINE; PROCEDURES; RISK FACTOR; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; HUMANS; LATENT TUBERCULOSIS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; RHEUMATIC DISEASES; RISK FACTORS; TUBERCULOSIS;

EID: 85066395053     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2019.1612872     Document Type: Review

References (110)

1. Singh JA, Saag KG, Bridges SL, Jr, et al. American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26.
2. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6–16.
3. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:529–535.
4. Souto A, Maneiro JR, Salgado E, et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014;53:1872–1885.
5. Baddley JW, Cantini F, Goletti D, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 2018;24(Suppl 2):S10–S20.
6. Winthrop KL, Mariette X, Silva JT, et al. ESCMID study group for infections in compromised hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24(Suppl 2):S21–S40.
7. Brassard P, Kezouh A, Suissa S., Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006;43:717–722.
8. Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35:387–393.
9. Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013;72:37–42.
10. de Vries MK, Arkema EV, Jonsson J, et al. ARTIS study group. tuberculosis risk in ankylosing spondylitis, other spondyloarthritis and psoriatic arthritis in Sweden: a population-based cohort study. Arthritis Care Res (Hoboken). 2017. Epub ahead of print. DOI:10.1002/acr.23487.
11. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–977.
12. Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum. 2009;61:300–304.
13. Wu CW, Wu JY, Lee MG, et al. Risk of incident active tuberculosis disease in patients treated with non-steroidal anti-inflammatory drugs: a population-based study. BMC Pulm Med. 2017;17:82.
14. Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14:503–509.
15. Goletti D, Petrone L, Ippolito G, et al. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther. 2018 Jun;16(6):501–512.
16. Tasillo A, Salomon JA, Trikalinos TA, et al. Cost-effectiveness of testing and treatment for latent tuberculosis infection in residents born outside the United States With and without medical comorbidities in a simulation model. JAMA Intern Med. 2017;177:1755–1764.
17. Nienhaus A, Schablon A, Costa JT, et al. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res. 2011;11:247.
18. Solomon L., Activation of latent infection by indomethacin: a report of three cases. Br Med J. 1966;1:961–962.
19. Brennan M. Activation of latent tuberculosis by nonsteroidal anti-inflammatory agents. Can Med Assoc J. 1980;122:400–402.
20. Brennan M. Latent tuberculosis and anti-inflammatory agents. Can Med Assoc J. 1982;126:21.
21. Tomasson HO, Brennan M, Bass MJ. Tuberculosis and nonsteroidal anti-inflammatory drugs. Can Med Assoc J. 1984;130:275–278.
22. Chen YJ, Wu CY, Shen JL, et al. Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan. J Am Acad Dermatol. 2013;69:25–33.
23. Wu CW, Wu JY, Lee MG, et al. Risk of incident active tuberculosis disease in patients treated with non-steroidal anti-inflammatory drugs: a population-based study. BMC Pulm Med. 2017;17:82.
24. Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheumatol Dis Clin N Am. 2016;42:157–176.
25. Bélard E, Semb S, Ruhwald M, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. 2011;17:2340–2349.
26. Perchanok M. Activation of healed pulmonary tuberculosis incidental to the use of cortisone in rheumatoid arthritis. A Case Report. Treat Serv Bull. 1951;6:321–328.
27. King EQ, Johnson JB, Batten GS, et al. Tuberculosis following cortisone therapy; report of a case of rapidly progressive pulmonary tuberculosis following cortisone therapy for rheumatoid arthritis. J Am Med Assoc. 1951;147:238–241.
28. Fred L, Levin MH, Rivo JB, et al. Development of active pulmonary tuberculosis during ACTH and cortisone therapy. J Am Med Assoc. 1951;147:242–246.
29. MacKinnon J. Tuberculosis occurring during steroid therapy. Br Med J. 1959;2:1375–1378.
30. Haanaes OC, Bergmann A. Tuberculosis emerging in patients treated with corticosteroids. Eur J Respir Dis. 1983;64:294–297.
31. Uthman I, Bizri AR, Hajj Ali R, et al. Miliary tuberculosis presenting as tenosynovitis in a case of rheumatoid arthritis. J Infect. 1998;37:196–198.
32. Hernández-Cruz B, Sifuentes-Osornio J, Ponce-de-León Rosales S, et al. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case-series. Clin Exp Rheumatol. 1999;17:289–296.
33. Kim HA, Yoo CD, Baek HJ, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol. 1998;16:9–13.
34. Dursun AB, Kalaç N, Ozkan B, et al. Pulmonary tuberculosis in patients with rheumatoid arthritis (four case reports). Rheumatol Int. 2002;21:153–157.
35. Tam LS, Li EK, Wong SM, et al. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol. 2002;31:296–300.
36. Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55:19–26.
37. Lai CC, Lee MT, Lee SH, et al. Risk of incident active tuberculosis and use of corticosteroids. Int J Tuberc Lung Dis. 2015;19:936–942.
38. Lai SW, Lin CL, Kf L. Nation-based case-control study investigating the relationship between oral corticosteroids use and pulmonary tuberculosis. Eur J Intern Med. 2017;43:53–57.
39. Brode SK, Jamieson FB, Ng R, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015;70:677–682.
40. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23:82–91.
41. Costedoat-Chalumeau N, Dunogué B, Morel N, et al. Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med. 2014;43:e167–e180.
42. Goldman FD, Gilman AL, Hollenback C, et al. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood. 2000;95:3460–3466.
43. Meier FM, Frerix M, Hermann W, et al. Current immunotherapy in rheumatoid arthritis. Immunotherapy. 2013;5:955–974.
44. Breedveld F, Dayer J. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000;59:841–849.
45. Miceli-Richard C, Dougados M. Leflunomide for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2003;4:987–997.
46. Hocevar A, Rozman B, Praprotnik S, et al. Leflunomide-associated tuberculosis? Rheumatology (Oxford). 2006;45:228–229.
47. Grover R, Dhir V, Aneja R, et al. Severe infections following leflunomide therapy for rheumatoid arthritis. Rheumatology (Oxford). 2006;45:918–920.
48. Agrawal S, Sharma A. Dual mycobacterial infection in the setting of leflunomide treatment for rheumatoid arthritis. Ann Rheum Dis. 2007;66:277.
49. Verma SK, Mishra AK, Jaiswal AK. Leflunomide-induced chronic cough in a rheumatoid arthritis patient with pulmonary tuberculosis. BMJ Case Rep. 2013 Feb 1;2013:bcr2012008373.
50. Jenks KA, Stamp LK, O‘Donnell JL, et al. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol. 2007;34:2201–2203.
51. Hong L, Wu JG, Ding JG, et al. Multifocal skeletal tuberculosis: experience in diagnosis and treatment. Med Mal Infect. 2010;40:6–11.
52. Yoo HG, Yu HM, Jun JB, et al. Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. Mod Rheumatol. 2013;23:709–715.
53. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65:168–173.
54. Hong W, Wang Y, Chang Z, et al. The identification of novel mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling. Sci Rep. 2015;5:15328.
55. Smith JD, Knox JM. Psoriasis, methotrexate and tuberculosis. Br J Dermatol. 1971;84:590–593.
56. Hodgson-Jones IS. Psoriasis, methotrexate and tuberculosis. Br J Dermatol. 1971;85:498.
57. Di Girolamo C, Pappone N, Melillo E, et al. Cavitary lung tuberculosis in a rheumatoid arthritis patient treated with low-dose methotrexate and steroid pulse therapy. Br J Rheumatol. 1998;37:1136–1137.
58. Binymin K, Cooper RG. Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology. 2001;40:341–342.
59. Huesler M, Ruef C, Pfyffer GE, et al. Peritoneal tuberculosis mimicking advanced ovarian cancer in a patient treated with methotrexate for chronic rheumatoid arthritis. J Obstet Gynaecol. 2003;23:315–316.
60. Zorlu M, Kiskac M, Karatoprak C, et al. Pott‘s disease and hypercalcemia in a patient with rheumatoid arthritis receiving methotrexate monotherapy. Indian J Pharmacol. 2013;45:631–633.
61. Natarajan V, John K, Jose D, et al. Portal venous thrombosis-disseminated tuberculosis in rheumatoid arthritis. J Clin Diagn Res. 2017;11:OD08–OD10.
62. Shaffrali FC, Colver GB, Messenger AG, et al. Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol. 2003;48:417–419.
63. Lamb SR. Methotrexate and reactivation tuberculosis. J Am Acad Dermatol. 2004;51:481–482.
64. Maejima H, Watarai A, Nakano T, et al. Adverse effects of methotrexate in three psoriatic arthritis patients. Rheumatol Int. 2014;34:571–574.
65. Matsuoka Y, Narukawa M. Comparison of serious adverse event profiles among antirheumatic agents using japanese adverse drug event report database. Ther Innov Regul Sci. 2018;52:339–347.
66. Lorenzetti R, Zullo A, Ridola L, et al. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Ann Med. 2014;46:547–554.
67. Baradat C, Degboé Y, Constantin A, et al. No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis. RMD Open. 2017;3:e000352.
68. Leitner J, Drobits K, Pickl WF, et al. The effects of cyclosporine A and azathioprine on human T cells activated by different costimulatory signals. Immunol Lett. 2011;140(1–2):74–80.
69. Ou SM, Liu CJ, Teng CJ, et al. Impact of pulmonary and extrapulmonary tuberculosis infection in kidney transplantation: a nationwide population-based study in Taiwan. Transpl Infect Dis. 2012;14:502–509.
70. Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003 Apr;111(8):1122–1124.
71. Katchamart W, Trudeau J, Phumethum V, et al. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2009;68:1105–1112.
72. Wu PH, Lin YT, Yang YH, et al. Increased risk of active tuberculosis disease in patients with dermatomyositis–a nationwide retrospective cohort study. Sci Rep. 2015;5:16303.
73. Cantini F, Nannini C, Niccoli L, et al. Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics. Mediators Inflamm. 2017;2017:8909834.
74. Harigai M, Ishiguro N, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2016;26:491–498.
75. Arjun MN, Hegde A, Vasdev V, et al. Abatacept in the management of refractory rheumatoid arthritis: experience at a teritiary care centre. Indian J Rheumatol. 2016;11(5 Supplement):S87.
76. Lim CH, Chen HH, Chen YH, et al. The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: a 15-year real world experience in Taiwan. PLoS One. 2017;12:e0178035.
77. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939–948.
78. Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76:1550–1558.
79. Goletti D, Petrone L, Ippolito G, et al. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther. 2018;16:501–512.
80. Morel J, Constantin A, Baron G, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatology (Oxford). 2017;56:1746–1754.
81. Choy E, Caporali R, Xavier R, et al. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018;57:1129.
82. Chen YM, Chen DY, HsiehLin CT, et al. Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis - A three-year study in Taiwan. J Microbiol Immunol Infect. 2017;pii:S1684-1182(17)30105–6.
83. Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73:1626–1634.
84. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67:1424–1437.
85. Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76:840–847.
86. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69:277–290.
87. Winthrop KL, Yamashita S, Beekmann SE, et al. Infectious diseases society of america emerging infections network. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the emerging infections network. Clin Infect Dis. 2008;46:1738–1740
88. Liao TL, Lin CH, Chen YM, et al. Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: a nationwide retrospective cohort study in Taiwan. PLoS One. 2016;11:e0153217.
89. Ottaviani S, Tiendrebeogo J, Choudat L, et al. Knee tuberculosis under rituximab therapy for rheumatoid arthritis. Joint Bone Spine. 2013;80:435–436.
90. Rutherford AI, Patarata E, Subesinghe S, et al. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the british society for rheumatology biologics register for rheumatoid arthritis. Rheumatology (Oxford). 2018;57:997–1001.
91. Olleros ML, Vesin D, Martinez-Soria E, et al. Interleukin-12p40 overexpression promotes interleukin-12p70 and interleukin-23 formation but does not affect bacille Calmette-Guérin and mycobacterium tuberculosis clearance. Immunology. 2007;122:350–361.
92. Sai TF, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167:1145–1152.
93. Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63:154–163.
94. Lynch M, Roche L, Horgan M, et al. Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis. JAAD Case Rep. 2017;14(3):230–232.
95. Kammüller M, Tsai TF, Griffiths CE, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunology 2017;6:e152.
96. Bélard E, Semb S, Ruhwald M, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011;17:2340–2349.
97. Arias-Guillén M, Sánchez Menéndez MM, Alperi M, et al. High rates of tuberculin skin test positivity due to methotrexate therapy: false positive results? Semin Arthritis Rheum 2018;48:538–546.
98. Kwakernaak AJ, Houtman PM, Weel JF, Spoorenberg JP, Jansen TL., A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor α inhibitor. Clin Rheumatol 2011;30:505–510.
99. Cuomo G, D’Abrosca V, Iacono D, Pantano I., The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis. Clin Rheumatol 2017; 36:457–461.
100. Cerda OL, de Los Angeles Correa M, Granel A, et al. Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy. Eur J Rheumatol 2019;6:19–22.
101. Chiacchio T, Petruccioli E, Vanini V, et al. Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases. J Infect. 2019 Apr 11. pii: S0163-4453(19)30122-7. doi: 10.1016/j.jinf.2019.04.010. [Epub ahead of print]
102. WHO Global Tuberculosis Report 2018. https://www.who.int/tb/publications/global_report/en/Accessed Feb2, 2019.
103. Greenberg JD, Reed G, Kremer JM, et al.; CORRONA Investigators. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010; 69:380–386.
104. Cantini F, Niccoli L, Goletti D., Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014;91:47–55.
105. Mullie GA, Schwartzman K, Zwerling A, et al. Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis. BMC Med 2017;15:104.
106. Public Health Agency of Canada. Canadian Tuberculosis Standards. Ottawa: Public Health Agency of Canada; 2007. [cited April2, 2012.] Available from: http://www.phac-aspc.gc.ca/tbpc-latb/pubs/tbstand07-eng.php.
107. Guidelines for Tuberculosis Control in New Zealand 2010 Chapter 8: diagnosis and treatment of latent tuberculosis infection. https://www.health.govt.nz/system/files/documents/publications/chapter8-guidelines-tuberculosis-control-new-zealand_0.
108. Duarte AC, Santos-Faria D, Gonçalves MJ, et al. Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update. Acta Reumatol Port 2017;42:127–140.
109. Buch MH, Smolen JS, Betteridge N, et al. Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909–920.
110. WHO. Latent TB Infection: 2018 Updated and consolidated guidelines for programmatic management. WHO/CDS/TB/2018.4. ISBN 978-92-4-155023-9.